Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Browse the world's most comprehensive archive of hedge fund manager letters. Access primary source research from leading institutional managers, sorted by reporting period.
The U.S. Concentrated Strategy posted a 2.39% net return in Q3 2025, lagging its value benchmark. The manager executed zero portfolio trades, maintaining steadfast conviction in detracted holdings like Keurig Dr Pepper and Molina Healthcare.
Full Quick Take
The U.S. Concentrated Strategy posted a 2.39% net return in Q3 2025, lagging its value benchmark. The manager executed zero portfolio trades, maintaining steadfast conviction in detracted holdings like Keurig Dr Pepper and Molina Healthcare.
Polen Focus Growth experienced a relative performance drag in Q2 2025 due to zero exposure to soaring semiconductors, but nimbly capitalized on market volatility to add to high-conviction compounders like Adobe and IDEXX.
Full Quick Take
Polen Focus Growth experienced a relative performance drag in Q2 2025 due to zero exposure to soaring semiconductors, but nimbly capitalized on market volatility to add to high-conviction compounders like Adobe and IDEXX.
Polen Global Growth underperformed the MSCI ACWI in Q2 2025, returning 7.87% net versus 11.53% for the index, heavily impacted by zero exposure to semiconductor cyclicals. The fund selectively added Starbucks and IDEXX Laboratories while fully exiting Globant.
Full Quick Take
Polen Global Growth underperformed the MSCI ACWI in Q2 2025, returning 7.87% net versus 11.53% for the index, heavily impacted by zero exposure to semiconductor cyclicals. The fund selectively added Starbucks and IDEXX Laboratories while fully exiting Globant.
